Somebody here (sorry, I can't recall who) asked the question recently about possible timeframes of various products to commercial registration.
From my enquiries, this seems to be a fairly reasonable expectation, subject to all going well...
IMP731 (GSK): GSK stated publicly that the program could be registered between 2021 – 2015 (subject to sufficient data etc of course)
IMP701 (Novartis): nothing stated publicly, but it would be reasonable to assume that from 2020 onwards a registration is possible
Efti (IMP321): AIPAC (metastatic breast cancer) PFS data next year, which could be the basis for an approval in Europe (subject to clinically meaningful data, safety etc.)
IMP761: preclinical, so comparably far away from commercialization.
.
Ann: Immutep enters into collaboration with MSD, page-22
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |